{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:10:48Z","timestamp":1794651048692,"version":"4.9.1"},"reference-count":292,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":134,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["C-2025-YXLH09"],"award-info":[{"award-number":["C-2025-YXLH09"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202206240086"],"award-info":[{"award-number":["202206240086"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People&apos;s Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["WKJ-ZJ-2517"],"award-info":[{"award-number":["WKJ-ZJ-2517"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Military Medical Research"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.mmr.2026.100038","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:25:06Z","timestamp":1779233106000},"page":"100038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Zhi-Peng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilinaer","family":"Wusiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premkamon","family":"Chaipanichkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzoamaka Adaobi","family":"Okoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siang Boon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheema","family":"Umber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Chao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib1","article-title":"Targeting mutant-p53 for cancer treatment: are we there yet?","volume":"17","author":"Lim","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.mmr.2026.100038_bib2","article-title":"Targeting of lysosomes as a therapeutic target in cancer","volume":"17","author":"Liu","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12876-025-03948-2","article-title":"Global burden of colon and rectal cancer and attributable risk factors in 204 countries and territories from 1990 to 2021","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib4","first-page":"12","article-title":"Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046","volume":"12","author":"Feng","year":"2025","journal-title":"Mil Med Res"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib5","first-page":"223","article-title":"Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study","volume":"4","author":"Li","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/hm.HM-D-24-00148","article-title":"Bridging cancer and cardiovascular health: a comprehensive review of cardiotoxicity in modern oncology","volume":"9","author":"Rajpoot","year":"2025","journal-title":"Heart and Mind"},{"key":"10.1016\/j.mmr.2026.100038_bib7","article-title":"Real-World Guide for delivering immunotherapy with radiation therapy","author":"Robinson","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"20","key":"10.1016\/j.mmr.2026.100038_bib8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mmr.2026.100038_bib9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41587-021-00954-z","article-title":"Drugmakers go nuclear, continuing push into radiopharmaceuticals","volume":"39","author":"Dolgin","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/pharmaceutics15010128","article-title":"Developments in combining targeted radionuclide therapies and immunotherapies for cancer treatment","volume":"15","author":"Kerr","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101232","article-title":"Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance","volume":"15","author":"Wang","year":"2025","journal-title":"J Pharm Anal"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.trecan.2023.07.014","article-title":"Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors","volume":"9","author":"Pouget","year":"2023","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1013247","article-title":"Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: modeling of amino acid infusion","volume":"21","author":"Golzaryan","year":"2025","journal-title":"PLoS Comput Biol"},{"issue":"ement 1","key":"10.1016\/j.mmr.2026.100038_bib18","article-title":"Image-based pharmacokinetic modeling and dosimetry: a paradigm for verification, validation and uncertainty quantification in computational nuclear oncology","volume":"66","author":"Zaid","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib19","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1038\/s41598-025-86159-9","article-title":"Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling","volume":"15","author":"Golzaryan","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41540-024-00362-4","article-title":"Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model","volume":"10","author":"Piranfar","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.mmr.2026.100038_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114310","article-title":"Charge-Switchable nanoparticles to enhance tumor penetration and accumulation","volume":"199","author":"Souri","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.mmr.2026.100038_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.est.2024.112561","article-title":"Using phase change material nanoparticles for thermal storage to protect healthy tissues by hyperthermia method assisted by a magnetic field for cancer tissue ablation","volume":"95","author":"Sarkesh","year":"2024","journal-title":"J Energy Storage"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2020","journal-title":"Medicina"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-025-02641-4","article-title":"Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies","volume":"42","author":"Shah","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.mmr.2026.100038_bib25","article-title":"Remodeling tumor immune microenvironment by using polymer-lipid-manganese dioxide nanoparticles with radiation therapy to boost immune response of castration-resistant prostate cancer","volume":"6","author":"Zetrini","year":"2023","journal-title":"Research (Wash D C)"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib26","first-page":"39","article-title":"Physical exercise reverses immuno-cold tumor microenvironment via inhibiting SQLE in non-small cell lung cancer","volume":"10","author":"Luo","year":"2023","journal-title":"Mil Med Res"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tips.2020.01.001","article-title":"The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers","volume":"41","author":"Kozlova","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.11.008","article-title":"YTE-17 inhibits colonic carcinogenesis by resetting antitumor immune response via Wnt5a\/JNK mediated metabolic signaling","volume":"14","author":"Sui","year":"2024","journal-title":"J Pharm Anal"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.21147\/j.issn.1000-9604.2024.06.03","article-title":"Microbiota and urinary tumor immunity: mechanisms, therapeutic implications, and future perspectives","volume":"36","author":"Li","year":"2024","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mdr2.70001","article-title":"Systematic investigation of tumor microenvironment and antitumor immunity with IOBR","volume":"1","author":"Fang","year":"2025","journal-title":"Med Research"},{"key":"10.1016\/j.mmr.2026.100038_bib31","article-title":"Immune escape: a critical hallmark in solid tumors","volume":"258","author":"Mortezaee","year":"2020","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/2211-5463.70018","article-title":"Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions","volume":"15","author":"Rafik","year":"2025","journal-title":"FEBS Open Bio"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrm3904","article-title":"Remodelling the extracellular matrix in development and disease","volume":"15","author":"Bonnans","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.21147\/j.issn.1000-9604.2024.02.05","article-title":"New roles of tumor-derived exosomes in tumor microenvironment","volume":"36","author":"Chen","year":"2024","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-020-00966-3","article-title":"Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment","volume":"13","author":"L\u00f3pez De Andr\u00e9s","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/cells11081294","article-title":"The role of extracellular vesicles in cancer-nerve crosstalk of the peripheral nervous system","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41573-024-01017-z","article-title":"Targeting the peripheral neural-tumour microenvironment for cancer therapy","volume":"23","author":"Yaniv","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.mmr.2026.100038_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9620870","article-title":"Genetic mutations and epigenetic modifications: driving cancer and informing precision medicine","volume":"2017","author":"Coyle","year":"2017","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib43","first-page":"21","article-title":"The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy","volume":"11","author":"Feng","year":"2024","journal-title":"Mil Med Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1120009X.2023.2300224","article-title":"The tumor microenvironment: shaping cancer progression and treatment response","volume":"37","author":"Desai","year":"2025","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.mmr.2026.100038_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108971","article-title":"The potential of targeted radionuclide therapy to treat hypoxic tumor cells","volume":"140-141","author":"Wenker","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.mmr.2026.100038_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1331364","article-title":"Immunological effects of radiopharmaceutical therapy","volume":"4","author":"Shea","year":"2024","journal-title":"Front Nucl Med"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib48","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ad6f15","article-title":"Microfluidic systems for modeling digestive cancer: a review of recent progress","volume":"10","author":"Razavi","year":"2024","journal-title":"Biomed Phys Eng Express"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib49","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib50","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.mmr.2026.100038_bib51","article-title":"Eubacterium rectale improves the efficacy of anti-PD1 immunotherapy in melanoma via l-serine-mediated NK cell activation","volume":"6","author":"Liu","year":"2023","journal-title":"Research (Wash D C)"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib52","article-title":"Advancements and challenges in brain cancer therapeutics","volume":"4","author":"Bai","year":"2024","journal-title":"Exploration (Beijing)"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib53","article-title":"Biomimetic and bioinspired nano-platforms for cancer vaccine development","volume":"3","author":"Feng","year":"2023","journal-title":"Exploration (Beijing)"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7150\/thno.79806","article-title":"Radiopharmaceuticals heat anti-tumor immunity","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"issue":"14","key":"10.1016\/j.mmr.2026.100038_bib55","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1096\/fj.02-0487fje","article-title":"Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery","volume":"16","author":"Sonveaux","year":"2002","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib56","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/pharmaceutics14071460","article-title":"Immune checkpoint inhibitor-mediated cancer theranostics with radiolabeled anti-granzyme B peptide","volume":"14","author":"De Aguiar Ferreira","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mmr.2026.100038_bib57","article-title":"Metal-phenolic network-facilitated \u201cfoe-to-friend\u201d conversion of melittin for cancer immunotherapy with boosted abscopal effect","volume":"6","author":"Guo","year":"2023","journal-title":"Research (Wash D C)"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib58","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.3390\/ijms22094843","article-title":"Combined radionuclide therapy and immunotherapy for treatment of triple negative breast cancer","volume":"22","author":"Vito","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mmr.2026.100038_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s42003-019-0327-4","article-title":"90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hernandez","year":"2019","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib61","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","article-title":"Cellular senescence in ageing: from mechanisms to therapeutic opportunities","volume":"22","author":"Di Micco","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.mmr.2026.100038_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkad001","article-title":"Characterization of cellular senescence in radiation ulcers and therapeutic effects of mesenchymal stem cell-derived conditioned medium","volume":"11","author":"Chen","year":"2023","journal-title":"Burns Trauma"},{"key":"10.1016\/j.mmr.2026.100038_bib64","article-title":"The common hallmarks and interconnected pathways of aging, circadian rhythms, and cancer: implications for therapeutic strategies","volume":"8","author":"Wang","year":"2025","journal-title":"Research (Wash D C)"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib65","first-page":"1483","article-title":"Cellular aging and senescence in cancer: a holistic review of cellular fate determinants","volume":"16","author":"Tufail","year":"2024","journal-title":"Aging Dis"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib66","article-title":"Targeting cellular senescence: a potential therapeutic approach for Alzheimer\u2019s disease","volume":"17","author":"Singh","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12943-024-02096-7","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib68","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","article-title":"Cellular senescence is immunogenic and promotes antitumor immunity","volume":"13","author":"Marin","year":"2023","journal-title":"Cancer Discov"},{"issue":"16","key":"10.1016\/j.mmr.2026.100038_bib69","doi-asserted-by":"crossref","first-page":"8675","DOI":"10.7150\/thno.112633","article-title":"The role of senescence, its therapeutic relevance and clinical implications in the tumor microenvironment","volume":"15","author":"Shi","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.mmr.2026.100038_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149774","article-title":"Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications","volume":"972","author":"Bacca","year":"2025","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib71","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.7150\/thno.31179","article-title":"Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics","volume":"9","author":"Timmermand","year":"2019","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib72","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/ph15091085","article-title":"Comparison of the anti-tumour activity of the somatostatin receptor (SST) antagonist [177Lu]Lu-satoreotide tetraxetan and the agonist [177Lu]Lu-DOTA-TATE in mice bearing AR42J SST2-positive tumours","volume":"15","author":"Plas","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib73","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.7150\/thno.82101","article-title":"Imaging DNA damage response by \u03b3H2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome","volume":"13","author":"O'neill","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.mmr.2026.100038_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122915","article-title":"Targeting senescence with radioactive 223Ra\/Ba SAzymes enables senolytics-unlocked one-two punch strategy to boost anti-tumor immunotherapy","volume":"315","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib75","article-title":"A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy","volume":"4","author":"Xie","year":"2023","journal-title":"Cell Rep Med"},{"issue":"602","key":"10.1016\/j.mmr.2026.100038_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib77","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/diagnostics3040344","article-title":"Induction of anti-tumor immune responses by peptide receptor radionuclide therapy with 177Lu-DOTATATE in a murine model of a human neuroendocrine tumor","volume":"3","author":"Wu","year":"2013","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib78","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41551-018-0262-6","article-title":"Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses","volume":"2","author":"Chao","year":"2018","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib79","first-page":"2661","article-title":"Effects of iodine-131 radiotherapy on Th17\/Tc17 and Treg\/Th17 cells of patients with differentiated thyroid carcinoma","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib80","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/RLU.0000000000001807","article-title":"Soft tissue response on 18F-fluorocholine PET\/CT in metastatic castrate-resistant prostate cancer treated with 223Ra-dichloride: a possible abscopal effect?","volume":"42","author":"Kwee","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.mmr.2026.100038_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667658","article-title":"Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Creemers","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib83","first-page":"82","article-title":"Role of PD-1\/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy","volume":"11","author":"Godiyal","year":"2024","journal-title":"Mil Med Res"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255798","article-title":"Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting","volume":"16","author":"Magee","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib86","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2967\/jnumed.122.264752","article-title":"Targeted \u03b1-therapy using 225Ac radiolabeled single-domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at the tumor microenvironment","volume":"64","author":"Ertveldt","year":"2023","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib87","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00262-020-02606-8","article-title":"Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy","volume":"69","author":"Rouanet","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"10.1016\/j.mmr.2026.100038_bib88","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"52","key":"10.1016\/j.mmr.2026.100038_bib89","doi-asserted-by":"crossref","first-page":"86937","DOI":"10.18632\/oncotarget.13520","article-title":"Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas\u2019 sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation","volume":"7","author":"Malamas","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib90","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-008-0449-x","article-title":"Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects","volume":"57","author":"Chakraborty","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"10.1016\/j.mmr.2026.100038_bib91","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/imt.13.16","article-title":"Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma","volume":"5","author":"Jandl","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.mmr.2026.100038_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563387","article-title":"Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer","volume":"16","author":"Ferreira","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib94","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s10439-024-03650-6","article-title":"A comparative analysis of alpha and beta therapy in prostate cancer using a 3D image-based spatiotemporal model","volume":"53","author":"Piranfar","year":"2025","journal-title":"Ann Biomed Eng"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib95","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s002590050286","article-title":"The importance of endothelium and interstitial fluid in nuclear medicine","volume":"25","author":"Peters","year":"1998","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40001-023-01627-0","article-title":"Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation","volume":"29","author":"Dhoundiyal","year":"2024","journal-title":"Eur J Med Res"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib97","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ad7592","article-title":"Mathematical modeling of 18F-fluoromisonidazole (18F-FMISO) radiopharmaceutical transport in vascularized solid tumors","volume":"10","author":"Abazari","year":"2024","journal-title":"Biomed Phys Eng Express"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18723-6","article-title":"Spatiotemporal multi-scale modeling of radiopharmaceutical distributions in vascularized solid tumors","volume":"12","author":"Kiani Shahvandi","year":"2022","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.mmr.2026.100038_bib99","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1111\/1759-7714.14655","article-title":"Evaluation of 99mTc-3PRGD2 SPECT imaging on angiogenesis in animal models of lung cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Thorac Cancer"},{"issue":"ement 1","key":"10.1016\/j.mmr.2026.100038_bib100","first-page":"1567","article-title":"PBPK-based histology-driven in silico tumor microenvironment model for PSMA-directed radioligand therapy","volume":"62","author":"Birindelli","year":"2021","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.mmr.2026.100038_bib101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3389\/fonc.2020.00562","article-title":"Tumor hypoxia: impact on radiation therapy and molecular pathways","volume":"10","author":"S\u00f8rensen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.mmr.2026.100038_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkad036","article-title":"Hypoxia macrophage-derived exosomal miR-26b-5p targeting PTEN promotes the development of keloids","volume":"12","author":"Dai","year":"2024","journal-title":"Burns Trauma"},{"issue":"14","key":"10.1016\/j.mmr.2026.100038_bib103","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.3390\/cancers13143429","article-title":"Is hypoxia a factor influencing PSMA-directed radioligand therapy? - An in silico study on the role of chronic hypoxia in prostate cancer","volume":"13","author":"Birindelli","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1874471011205020099","article-title":"Tumour hypoxia and technetium tracers: in vivo studies","volume":"5","author":"Abrantes","year":"2012","journal-title":"Curr Radiopharm"},{"issue":"25","key":"10.1016\/j.mmr.2026.100038_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201700640","article-title":"Albumin-templated manganese dioxide nanoparticles for enhanced radioisotope therapy","volume":"13","author":"Tian","year":"2017","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib106","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/pr.109.001289","article-title":"Extracellular matrix molecules: potential targets in pharmacotherapy","volume":"61","author":"J\u00e4rvel\u00e4inen","year":"2009","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib107","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.7150\/thno.39995","article-title":"Towards extracellular matrix normalization for improved treatment of solid tumors","volume":"10","author":"Abyaneh","year":"2020","journal-title":"Theranostics"},{"issue":"21","key":"10.1016\/j.mmr.2026.100038_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206370","article-title":"Nanoparticle-mediated radiotherapy remodels the tumor microenvironment to enhance antitumor efficacy","volume":"35","author":"Zhen","year":"2023","journal-title":"Adv Mater"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib109","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00604-024-06583-y","article-title":"Intertumoral and intratumoral barriers as approaches for drug delivery and theranostics to solid tumors using stimuli-responsive materials","volume":"191","author":"Chenab","year":"2024","journal-title":"Mikrochim Acta"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib110","doi-asserted-by":"crossref","DOI":"10.1063\/1.5134421","article-title":"Radiopharmaceutical dose distribution in different organs and tissues for Lu-177 with different carrier","volume":"2174","author":"Zakaly","year":"2019","journal-title":"AIP Conf Proc"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib111","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/bip.21218","article-title":"Specific labeling with potent radiolabels alters the uptake of cell-penetrating peptides","volume":"92","author":"Walther","year":"2009","journal-title":"Biopolymers"},{"key":"10.1016\/j.mmr.2026.100038_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108050","article-title":"Effect of tumor heterogeneity on enhancing drug delivery to vascularized tumors using thermo-sensitive liposomes triggered by hyperthermia: a multi-scale and multi-physics computational model","volume":"170","author":"Tehrani","year":"2024","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.mmr.2026.100038_bib113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2015.00165","article-title":"Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid","volume":"5","author":"Baronzio","year":"2015","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib114","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3390\/cells10113041","article-title":"The effects of ionising and non-ionising electromagnetic radiation on extracellular matrix proteins","volume":"10","author":"Tuieng","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib115","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1887552","article-title":"Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment","volume":"10","author":"Han","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib116","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2127507","article-title":"Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo","volume":"11","author":"Gargiulo","year":"2022","journal-title":"Oncoimmunology"},{"issue":"19","key":"10.1016\/j.mmr.2026.100038_bib117","first-page":"4468","article-title":"Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells","volume":"58","author":"Dolo","year":"1998","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib118","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/cr.2014.44","article-title":"Double-stranded DNA in exosomes: a novel biomarker in cancer detection","volume":"24","author":"Thakur","year":"2014","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib119","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09553002.2021.1955999","article-title":"Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy","volume":"99","author":"Karam","year":"2023","journal-title":"Int J Radiat Biol"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib120","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-20-4790","article-title":"Radium-223 treatment increases immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment","volume":"27","author":"Vardaki","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7378","key":"10.1016\/j.mmr.2026.100038_bib122","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.mmr.2026.100038_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114585","article-title":"Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy","volume":"191","author":"Zhao","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib124","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12967-022-03409-4","article-title":"Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review","volume":"20","author":"Kov\u00e1cs","year":"2022","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"10.1016\/j.mmr.2026.100038_bib126","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.7150\/thno.54881","article-title":"Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy","volume":"11","author":"Jagodinsky","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib127","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acsptsci.0c00206","article-title":"PARP targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma","volume":"4","author":"Dabagian","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40824-022-00290-6","article-title":"Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy\/chemodynamic therapy to discourage cancer progression","volume":"26","author":"Zhang","year":"2022","journal-title":"Biomater Res"},{"issue":"25","key":"10.1016\/j.mmr.2026.100038_bib129","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1v\u03b23-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2000699","article-title":"CS1-specific single-domain antibodies labeled with actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in multiple myeloma","volume":"10","author":"De Veirman","year":"2021","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib131","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2967\/jnumed.118.209510","article-title":"Combined VLA-4-targeted radionuclide therapy and immunotherapy in a mouse model of melanoma","volume":"59","author":"Choi","year":"2018","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib132","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib133","article-title":"Nanodrugs with intrinsic radioprotective exertion: turning the double-edged sword into a single-edged knife","volume":"3","author":"Guo","year":"2023","journal-title":"Exploration (Beijing)"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.12.018","article-title":"Design of a nanozyme-based magnetic nanoplatform to enhance photodynamic therapy and immunotherapy","volume":"14","author":"Bai","year":"2024","journal-title":"J Pharm Anal"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpan.2024.11.001","article-title":"Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies","volume":"21","author":"Chen","year":"2024","journal-title":"Curr Pharm Anal"},{"key":"10.1016\/j.mmr.2026.100038_bib136","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.biomaterials.2019.01.033","article-title":"Nanoparticle-mediated internal radioisotope therapy to locally increase the tumor vasculature permeability for synergistically improved cancer therapies","volume":"197","author":"Liang","year":"2019","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202417027","article-title":"Bifunctional metal-organic framework synergistically enhances radiotherapy and activates STING for potent cancer radio-immunotherapy","volume":"64","author":"Wang","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.mmr.2026.100038_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122795","article-title":"Responsive and traceless assembly of iron nanoparticles and 131I labeled radiopharmaceuticals for ferroptosis enhanced radio-immunotherapy","volume":"313","author":"Shen","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.mmr.2026.100038_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/imm3.70007","article-title":"The future of cancer therapy: nanomaterials and tumor microenvironment","volume":"1","author":"Chen","year":"2025","journal-title":"iMetaMed"},{"key":"10.1016\/j.mmr.2026.100038_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108970","article-title":"Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL\/6J mice with orthotopic GL261 murine glioma tumors","volume":"140-141","author":"Georgiou","year":"2025","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2024.01.01","article-title":"Manufacturing CAR-NK against tumors: who is the ideal supplier?","volume":"36","author":"Guo","year":"2024","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib142","first-page":"52","article-title":"Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer","volume":"10","author":"Tang","year":"2023","journal-title":"Mil Med Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib143","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers16010191","article-title":"Comparative study of the effect of radiation delivered by lutetium-177 or actinium-225 on anti-GD2 chimeric antigen receptor T cell viability and functions","volume":"16","author":"Sodji","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mmr.2026.100038_bib144","article-title":"Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.mmr.2026.100038_bib146","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mdb2.70002","article-title":"Advances and challenges in pluripotent stem cell\u2010based whole\u2010cell vaccines for cancer treatment","volume":"1","author":"Wan","year":"2025","journal-title":"Medicine Bulletin"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib147","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"issue":"42","key":"10.1016\/j.mmr.2026.100038_bib148","doi-asserted-by":"crossref","first-page":"69014","DOI":"10.18632\/oncotarget.10883","article-title":"Samarium-153-EDTMP (Quadramet\u00ae) with or without vaccine in metastatic castration-resistant prostate cancer: a randomized phase 2 trial","volume":"7","author":"Heery","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib149","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib150","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2967\/jnumed.122.264126","article-title":"Improved tumor responses with sequential targeted \u03b1-particles followed by interleukin 2 immunocytokine therapies in treatment of CEA-positive breast and colon tumors in CEA transgenic mice","volume":"63","author":"Minnix","year":"2022","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib151","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2967\/jnumed.124.268200","article-title":"Preclinical evaluation of 177Lu-OncoFAP-23, a multivalent FAP-targeted radiopharmaceutical therapeutic for solid tumors","volume":"65","author":"Galbiati","year":"2024","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib152","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3390\/ph17121663","article-title":"Visualizing the tumor microenvironment: molecular imaging probes target extracellular matrix, vascular networks, and immunosuppressive cells","volume":"17","author":"Chan","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib153","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12032-025-03061-0","article-title":"Theranostics in nuclear medicine: the era of precision oncology","volume":"42","author":"Gandhi","year":"2025","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib154","first-page":"549","article-title":"89Zr-labeled anti-PD-L1 antibody fragment for evaluating in vivo PD-L1 levels in melanoma mouse model","volume":"35","author":"Bridgwater","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib155","first-page":"154","article-title":"Preclinical development and characterisation of 99mTc-NM-01 for SPECT\/CT imaging of human PD-L1","volume":"11","author":"Wong","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"24","key":"10.1016\/j.mmr.2026.100038_bib156","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1158\/1078-0432.CCR-22-1379","article-title":"Monitoring therapeutic response to anti-FAP CAR T cells using [18F]AlF-FAPI-74","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib157","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12967-023-04142-2","article-title":"Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13R\u03b12 after radiolabeling with 89Zirconium oxine for PET imaging","volume":"21","author":"Leland","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.mmr.2026.100038_bib158","unstructured":"PD-L1 targeting nanobody probe for PET imaging of solid tumor. 2021. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05156515\u3009. Accessed 1st August 2025."},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib159","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00259-024-06999-x","article-title":"Human dose-escalation study of PET imaging CD8+ T-cell infiltration in solid malignancies with [68Ga]Ga-NODAGA-SNA006","volume":"52","author":"Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.mmr.2026.100038_bib160","unstructured":"A phase IIB, open label, study of zirconium Zr 89 crefmirlimab berdoxam PET\/CT in subjects with advanced or metastatic malignancies, scheduled to receive immunotherapy (IOT) as a single agent or combination, to predict response to therapy. 2021. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05013099\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib161","unstructured":"Safety study of 89Zr-labeled KN035 PET imaging in patients with PD-L1 positive solid tumors. 2021. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04977128\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib162","unstructured":"A phase I study of 64Cu pembrolizumab PET imaging for in vivo expression of PD1. 2020. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04605614\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib163","unstructured":"Programmed death-ligand 1 positron emission tomography imaging during neoadjuvant (chemo)radiotherapy in esophageal and rectal cancer (PETNEC): a prospective non-randomized open-label single-center pilot study. 2020. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04564482\u3009. Accessed 13 August 2025."},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib164","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12149-024-02009-0","article-title":"Radiolabelled anti-PD-L1 peptide PET\/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer","volume":"39","author":"Zhou","year":"2025","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.mmr.2026.100038_bib165","unstructured":"A phase 1, first-in-human study of immunoPET imaging of PD-L1 in tumors using 89Zr-DFO-REGN3504, an anti-PD-L1 tracer for positron emission tomography in patients with advanced PD-L1 positive malignancies. 2018. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03746704\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib166","unstructured":"Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma. 2017. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03313323\u3009. Accessed 1st August 2025."},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib167","first-page":"720","article-title":"CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody","volume":"63","author":"Farwell","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.mmr.2026.100038_bib168","unstructured":"89Zr-pembrolizumab-PET imaging in patients with locally advanced or metastatic melanoma or non-small cell lung cancer. 2016. \u3008https:\/\/clinicaltrials.gov\/study\/NCT02760225\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib169","unstructured":"89Zirconium-labeled pembrolizumab as predictive imaging biomarker of response and toxicity in pembrolizumab treated patients with non-small-cell lung cancer - a feasibility study. 2017. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03065764\u3009. Accessed 1st August 2025."},{"issue":"16_","key":"10.1016\/j.mmr.2026.100038_bib170","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib171","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16_","key":"10.1016\/j.mmr.2026.100038_bib172","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","article-title":"177Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)","volume":"43","author":"Sandhu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib173","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2967\/jnumed.120.249029","article-title":"First experiences with 177Lu-PSMA therapy in combination with pembrolizumab or after pretreatment with olaparib in single patients","volume":"62","author":"Prasad","year":"2021","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib174","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005383","article-title":"First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer","volume":"10","author":"Digklia","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the 177Lu-DOTA0-Tyr3-octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","author":"Kim","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib176","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2967\/jnumed.121.262344","article-title":"Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic merkel cell carcinoma","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib177","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib178","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-20-4476","article-title":"Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer","volume":"27","author":"Marshall","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.mmr.2026.100038_bib179","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"A phase Ib study of Atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib180","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib181","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00270-018-1993-1","article-title":"Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma","volume":"41","author":"Wehrenberg-Klee","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib182","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of ccombined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma","volume":"31","author":"Zhan","year":"2020","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib183","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1634\/theoncologist.2019-0924","article-title":"A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib184","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","article-title":"Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series","volume":"29","author":"Zheng","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.mmr.2026.100038_bib185","unstructured":"A single arm study with safety run-in of peptide receptor radionuclide therapy (PRRT) in combination with immunotherapy for patients with merkel cell cancer (HCRN MCC20-443; iPRRT Study). 2022. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05583708\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib186","unstructured":"A phase 2 open-label study of nivolumab combined with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with clear cell advanced renal cell carcinoma. 2022. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05239533\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib187","unstructured":"Phase II study of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with ipilimumab and nivolumab for men with metastaticcastration resistant prostate cancer (mCRPC). 2021. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05150236\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib188","unstructured":"A phase Ib\/II dose finding study assessing safety and efficacy of [177Lu]Lu-DOTA-TATE in newly diagnosed extensive stage small cell lung cancer (ES-SCLC) in combination with carboplatin, etoposide, and atezolizumab in induction and with atezolizumab in maintenance phase. 2021. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05142696\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib189","unstructured":"Phase I\/II trial of pembrolizumab and androgen-receptor inhibitor with or without 225Ac-J591 for progressive metastatic castration resistant prostate cancer. 2021. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04946370\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib190","unstructured":"A phase II single arm trial evaluating the preliminary efficacy of the combination of 177Lu-DOTATATE and nivolumab in grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC). 2020. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04525638\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib191","unstructured":"A phase Ib\/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractionated radiotherapy in patients with metastatic merkel cell carcinoma. 2020. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04261855\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib192","unstructured":"A phase IB study of nivolumab in combination with radium-223 in men with metastatic castration resistant prostate cancer. 2019. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04109729\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib193","unstructured":"Immunotherapy combined with yttrium-90 radioembolization in the treatment of colorectal cancer with liver metastases [iRE-C - Clinical Trial]. 2019. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04108481?tab=history\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib194","unstructured":"A phase I and randomized phase II trial of radium-223 dichloride, M3814 plus avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC). 2019. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04071236\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib195","unstructured":"An open-label, multicenter, phase 1\/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer. 2019. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03996473\u3009. Accessed 13 August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib196","first-page":"2025","author":"A pilot study of pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and\/or progressive metastases","year":"2018","journal-title":"Accessed 13 August"},{"key":"10.1016\/j.mmr.2026.100038_bib197","unstructured":"Radioiodine (RAI) in combination with durvalumab (Medi4736) for RAI-avid, recurrent\/metastatic thyroid cancers. 2017. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03215095\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib198","unstructured":"A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma with preserved liver function. HCRN: GI15-225. 2017. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03099564\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib199","unstructured":"A phase I study of 131-1 mIBG followed by nivolumab and dinutuximab beta in children with relapsed\/refractory neuroblastoma. 2016. \u3008https:\/\/clinicaltrials.gov\/study\/NCT02914405\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib200","unstructured":"A feasibility study of sequential hepatic internal radiation and systemic ipilimumab and nivolumab in patients with uveal melanoma metastatic to liver. 2016. \u3008https:\/\/clinicaltrials.gov\/study\/NCT02913417\u3009. Accessed 1st August 2025."},{"key":"10.1016\/j.mmr.2026.100038_bib201","unstructured":"Pilot study of sequential hepatic radioembolization and systemic ipilimumab in patients with uveal melanoma metastatic to liver. 2012. \u3008https:\/\/clinicaltrials.gov\/study\/NCT01730157\u3009. Accessed 1st August 2025."},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib202","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib203","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib204","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","article-title":"Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib205","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol Pharm"},{"issue":"22","key":"10.1016\/j.mmr.2026.100038_bib206","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib207","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40658-022-00497-5","article-title":"Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model","volume":"9","author":"Tranel","year":"2022","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib208","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41540-024-00467-w","article-title":"Enhancing localized chemotherapy with anti-angiogenesis and nanomedicine synergy for improved tumor penetration in well-vascularized tumors","volume":"10","author":"Souri","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib209","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics13071025","article-title":"Two novel PET radiopharmaceuticals for endothelial vascular cell adhesion molecule-1 (VCAM-1) targeting","volume":"13","author":"Pastorino","year":"2021","journal-title":"Pharmaceutics"},{"issue":"16","key":"10.1016\/j.mmr.2026.100038_bib210","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.3390\/ijms241612675","article-title":"NGR-based radiopharmaceuticals for angiogenesis imaging: a preclinical review","volume":"24","author":"Trencs\u00e9nyi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib211","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00109-012-0965-1","article-title":"Radiation-induced galectin-1 by endothelial cells: a promising molecular target for preferential drug delivery to the tumor vasculature","volume":"91","author":"Upreti","year":"2013","journal-title":"J Mol Med (Berl)"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib212","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2174\/1568026623666230515154442","article-title":"Insight into tumor hypoxia: radionuclide-based biomarker as diagnostic tools","volume":"23","author":"Saxena","year":"2023","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.mmr.2026.100038_bib213","first-page":"316","article-title":"3D bioprinted breast cancer model reveals stroma-mediated modulation of extracellular matrix and radiosensitivity","volume":"42","author":"Desigaux","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.mmr.2026.100038_bib214","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2024.10.010","article-title":"Biomaterials to regulate tumor extracellular matrix in immunotherapy","volume":"376","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.mmr.2026.100038_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216859","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities","volume":"591","author":"Qin","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.mmr.2026.100038_bib216","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.mmr.2026.100038_bib217","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2014.05.019","article-title":"Improving the distribution of Doxil\u00ae in the tumor matrix by depletion of tumor hyaluronan","volume":"191","author":"Kohli","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.mmr.2026.100038_bib218","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jconrel.2018.11.022","article-title":"Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy","volume":"293","author":"Guan","year":"2019","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib219","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib220","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114851119","article-title":"D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"10.1016\/j.mmr.2026.100038_bib221","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202207343","article-title":"Metabolic homeostasis-regulated nanoparticles for antibody-independent cancer radio-immunotherapy","volume":"34","author":"Shen","year":"2022","journal-title":"Adv Mater"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib222","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.matt.2019.06.007","article-title":"Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers","volume":"1","author":"Ni","year":"2019","journal-title":"Matter"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib223","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.mmr.2026.100038_bib224","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1021\/acs.nanolett.1c03243","article-title":"Engineered nanovaccine targeting Clec9a+ dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist","volume":"21","author":"Gou","year":"2021","journal-title":"Nano Lett"},{"issue":"45","key":"10.1016\/j.mmr.2026.100038_bib225","doi-asserted-by":"crossref","first-page":"42661","DOI":"10.1021\/acsami.9b16814","article-title":"Bioactive polysaccharide nanoparticles improve radiation-induced abscopal effect through manipulation of dendritic cells","volume":"11","author":"Pang","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"10.1016\/j.mmr.2026.100038_bib226","doi-asserted-by":"crossref","first-page":"8450","DOI":"10.1021\/acsnano.0c10764","article-title":"Zoledronic acid-gadolinium coordination polymer nanorods for improved tumor radioimmunotherapy by synergetically inducing immunogenic cell death and reprogramming the immunosuppressive microenvironment","volume":"15","author":"Huang","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.mmr.2026.100038_bib227","first-page":"359","article-title":"Polarization of tumor-associated macrophages by TLR7\/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance","volume":"16","author":"Zhang","year":"2022","journal-title":"Bioact Mater"},{"key":"10.1016\/j.mmr.2026.100038_bib228","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mattod.2022.10.018","article-title":"Tumor extracellular matrix-targeted nanoscavengers reverse suppressive microenvironment for cocktail therapy","volume":"61","author":"Chen","year":"2022","journal-title":"Materials Today"},{"key":"10.1016\/j.mmr.2026.100038_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.sna.2024.115625","article-title":"CRISPR-microfluidics nexus: advancing biomedical applications for understanding and detection","volume":"376","author":"Razavi","year":"2024","journal-title":"Sensors and Actuators A: Physical"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib230","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.trecan.2023.05.002","article-title":"Neuro-immune interactions and immuno-oncology","volume":"9","author":"Khanmammadova","year":"2023","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib231","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: state of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib232","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/2159-8290.CD-23-0397","article-title":"Nerves at Play: The peripheral nervous system in extracranial malignancies","volume":"15","author":"Vermeer","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.mmr.2026.100038_bib233","doi-asserted-by":"crossref","unstructured":"Che X., Wang H., Wang H., Jiang Y.Z. Intratumoral nerve phased development: a promising therapeutic target. Medicine Bulletin.1(2):154-170. https:\/\/doi.org\/10.1002\/mdb2.70009.","DOI":"10.1002\/mdb2.70009"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib234","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc1820","article-title":"The influence of bio-behavioural factors on tumour biology: pathways and mechanisms","volume":"6","author":"Antoni","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib235","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cam4.4488","article-title":"Neurobiology of cancer: definition, historical overview, and clinical implications","volume":"11","author":"Mravec","year":"2022","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib236","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-019-0566-4","article-title":"Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib237","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/hm.HM-D-24-00088","article-title":"Body image and self-identity in transgender patients: a comprehensive review from a psycho-oncological perspective","volume":"9","author":"Marano","year":"2025","journal-title":"Heart and Mind"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib238","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13046-023-02728-8","article-title":"Chronic stress accelerates glioblastoma progression via DRD2\/ERK\/\u03b2-catenin axis and dopamine\/ERK\/TH positive feedback loop","volume":"42","author":"Wang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib239","article-title":"Telemedicine-medical \u201csnack community\u201d-PHS ecosystem: insights into the double-edged sword role of telemedicine in clinical practice and medical education during the COVID-19 pandemic and beyond","volume":"4","author":"Feng","year":"2024","journal-title":"Exploration (Beijing)"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib240","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41467-018-05283-5","article-title":"Modulation of anti-tumor immunity by the brain\u2019s reward system","volume":"9","author":"Ben-Shaanan","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib241","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Fj\u00e6stad","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib242","first-page":"305","article-title":"The effect of a group cognitive behavioral therapy on the quality of life and emotional disturbance of women with breast cancer","volume":"30","author":"Jelvehzadeh","year":"2022","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.mmr.2026.100038_bib243","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41568-025-00831-w","article-title":"Neuro-immune cross-talk in cancer","volume":"25","author":"Amit","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.mmr.2026.100038_bib244","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1158\/0008-5472.CAN-12-0764","article-title":"Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor","volume":"72","author":"Cavel","year":"2012","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.mmr.2026.100038_bib245","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-17-1612","article-title":"Inflammatory monocytes promote perineural invasion via CCL2-mediated recruitment and cathepsin B expression","volume":"77","author":"Bakst","year":"2017","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib246","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc3978","article-title":"Sympathetic nervous system regulation of the tumour microenvironment","volume":"15","author":"Cole","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib247","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.3390\/ijms26062553","article-title":"Neuroimmune interactions and their role in immune cell trafficking in cardiovascular diseases and cancer","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib248","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10555-025-10241-x","article-title":"Sympathetic nerve signaling rewires the tumor microenvironment: a shift in \u201cmicroenvironmental-ity","volume":"44","author":"Sattler","year":"2025","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib249","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.4049\/jimmunol.2100719","article-title":"The sympathetic nervous system modulates cancer vaccine activity through monocyte-derived cells","volume":"207","author":"Hinkle","year":"2021","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib250","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/2159-8290.CD-18-0046","article-title":"Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness","volume":"8","author":"Renz","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib251","article-title":"Mechanical forces in tumor growth and treatment: perspectives from biology, physics, engineering, and mathematical modeling","volume":"17","author":"Moradi Kashkooli","year":"2025","journal-title":"WIREs Mech Dis"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib252","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039925","article-title":"Radiation impairs perineural invasion by modulating the nerve microenvironment","volume":"7","author":"Bakst","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib253","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1245\/s10434-020-08667-4","article-title":"Perineural invasion is a better prognostic indicator than lymphovascular invasion and a potential adjuvant therapy indicator for pN0M0 esophageal squamous cell carcinoma","volume":"27","author":"Guo","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib254","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijrobp.2022.09.080","article-title":"Radiation therapy exacerbates tumor-promoting innervation and nerve signaling in rectal cancer","volume":"115","author":"Uccello","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib255","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.radonc.2012.10.012","article-title":"Radiation-induced neuropathy in cancer survivors","volume":"105","author":"Delanian","year":"2012","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib256","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-010-0309-3","article-title":"Radiation-induced changes in peripheral nerve by stereotactic radiosurgery: a study on the sciatic nerve of rabbit","volume":"102","author":"Lin","year":"2011","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib257","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/brain\/awaf163","article-title":"Disruption of DNA methylation underpins the neuroinflammation induced by targeted CNS radiotherapy","volume":"148","author":"Millner","year":"2025","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib258","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mdr2.70006","article-title":"Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development","volume":"1","author":"Gao","year":"2025","journal-title":"Med Research"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib259","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.mmr.2026.100038_bib261","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1007\/s00259-023-06364-4","article-title":"Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting","volume":"50","author":"Damiana","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib262","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib263","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.mmr.2026.100038_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib265","first-page":"237","article-title":"Overcoming cancer treatment resistance: Unraveling the role of cancer-associated fibroblasts","volume":"5","author":"Wang","year":"2025","journal-title":"J Natl Cancer Cent"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib266","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib267","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J Med Radiat Sci"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib268","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.mmr.2026.100038_bib269","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.semnuclmed.2024.09.008","article-title":"Current and future perspectives of PDL1 PET and SPECT imaging","volume":"54","author":"Dev","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib270","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semradonc.2024.04.004","article-title":"The effects of radiation dose heterogeneity on the tumor microenvironment and anti-tumor immunity","volume":"34","author":"Takashima","year":"2024","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.mmr.2026.100038_bib271","doi-asserted-by":"crossref","DOI":"10.1002\/brx2.70030","article-title":"From digitized whole-slide histology images to biomarker discovery: a protocol for handcrafted feature analysis in brain cancer pathology","volume":"3","author":"Lu","year":"2025","journal-title":"Brain\u2010X"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib272","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.mmr.2026.100038_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102524","article-title":"Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer","volume":"115","author":"Calais","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"Pt 2","key":"10.1016\/j.mmr.2026.100038_bib274","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2017.12.007","article-title":"Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers","volume":"52","author":"Lhuillier","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10.1016\/j.mmr.2026.100038_bib275","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-21-0791","article-title":"Targeted radionuclide therapy with low and high-dose lutetium-177-labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model","volume":"21","author":"Ertveldt","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"2_ement","key":"10.1016\/j.mmr.2026.100038_bib276","doi-asserted-by":"crossref","first-page":"P006","DOI":"10.1158\/1557-3265.TARGETEDTHERAP-P006","article-title":"Abstract P006: partial tumor volume irradiation by 177Lu-PNT6555 induces diverse immune responses in a syngeneic murine tumor model","volume":"31","author":"Takashima","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.mmr.2026.100038_bib277","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1655964","article-title":"Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients","volume":"8","author":"Rodriguez-Ruiz","year":"2019","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib278","doi-asserted-by":"crossref","first-page":"341","DOI":"10.21147\/j.issn.1000-9604.2024.03.09","article-title":"Unraveling links between aging, circadian rhythm and cancer: insights from evidence-based analysis","volume":"36","author":"Feng","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.mmr.2026.100038_bib279","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkae075","article-title":"Basic helix-loop-helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases","volume":"13","author":"Shao","year":"2025","journal-title":"Burns Trauma"},{"issue":"4","key":"10.1016\/j.mmr.2026.100038_bib280","first-page":"2073","article-title":"Crosstalk between circadian rhythm dysregulation and tumorigenesis, tumor metabolism and tumor immune response","volume":"16","author":"Zhu","year":"2024","journal-title":"Aging Dis"},{"issue":"10","key":"10.1016\/j.mmr.2026.100038_bib281","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002387","article-title":"Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy","volume":"9","author":"Lejeune","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.mmr.2026.100038_bib282","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/ijms21030773","article-title":"Evaluating the combination of radioimmunotherapy and immunotherapy in a melanoma mouse model","volume":"21","author":"Jiao","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mmr.2026.100038_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.216801","article-title":"Smart nanomaterials for multimodal theranostics and tissue regeneration","volume":"541","author":"Lee","year":"2025","journal-title":"Coordination Chemistry Reviews"},{"issue":"17","key":"10.1016\/j.mmr.2026.100038_bib284","article-title":"3D-printed functional hydrogel by DNA-induced biomineralization for accelerated diabetic wound healing","volume":"10","author":"Kim","year":"2023","journal-title":"Adv Sci"},{"issue":"18","key":"10.1016\/j.mmr.2026.100038_bib285","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202308912","article-title":"Expanding the horizons of machine learning in nanomaterials to chiral nanostructures","volume":"36","author":"Kuznetsova","year":"2024","journal-title":"Adv Mater"},{"issue":"12","key":"10.1016\/j.mmr.2026.100038_bib286","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41578-023-00581-x","article-title":"New opportunities and old challenges in the clinical translation of nanotheranostics","volume":"8","author":"Gawne","year":"2023","journal-title":"Nat Rev Mater"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib287","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-024-45072-x","article-title":"In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence\/metastasis and wound healing","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.mmr.2026.100038_bib288","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.7150\/thno.93973","article-title":"Theranostic digital twins: concept, framework and roadmap towards personalized radiopharmaceutical therapies","volume":"14","author":"Abdollahi","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib289","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41181-023-00236-w","article-title":"Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding","volume":"9","author":"Fele-Paranj","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-021-01764-y","article-title":"Radiation-induced kidney toxicity: molecular and cellular pathogenesis","volume":"16","author":"Klaus","year":"2021","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.mmr.2026.100038_bib291","doi-asserted-by":"crossref","DOI":"10.1002\/brx2.7","article-title":"Nucleic acid delivery by ionizable nanocarriers for brain disease treatment","volume":"1","author":"Xiong","year":"2023","journal-title":"Brain\u2010X"},{"key":"10.1016\/j.mmr.2026.100038_bib292","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123120","article-title":"CRISPR innovations in tissue engineering and gene editing","volume":"358","author":"Razavi","year":"2024","journal-title":"Life Sci"}],"container-title":["Military Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2054936926000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2054936926000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:14:06Z","timestamp":1783174446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2054936926000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":292,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2054936926000506"],"URL":"https:\/\/doi.org\/10.1016\/j.mmr.2026.100038","relation":{},"ISSN":["2054-9369"],"issn-type":[{"value":"2054-9369","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Military Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mmr.2026.100038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of Military Science Publishing House.","name":"copyright","label":"Copyright"}],"article-number":"100038"}}